Drug
Bimiralisib clinical trials
Also written PQR309.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
PIQUR Therapeutics AG (8) · TORQUR (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses bimiralisib is read from its arms, and is right about nine times in ten.
Testing it · 10
- Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic KeratosisCompletedPhase 2TORQURNCT06319794Written as Bimiralisib
- Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function MutationsTerminatedPhase 2M.D. Anderson Cancer CenterNCT03740100Written as Bimiralisib
- Open-Label, Non Randomized Phase 2 Study With Safety Run-InCompletedPhase 2PIQUR Therapeutics AGNCT02249429Written as bimiralisib
- PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaCompletedPhase 2PIQUR Therapeutics AGNCT02669511Written as PQR309
- Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma PatientsCompletedPhase 2PIQUR Therapeutics AGNCT03127020Written as PQR309
- Study of Oral PQR309 in Patients With Advanced Solid TumorsCompletedPhase 1PIQUR Therapeutics AGNCT02483858Written as PQR 309
- PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)CompletedPhase 1/2PIQUR Therapeutics AGNCT02723877Written as PQR309
- PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaWithdrawnPhase 2PIQUR Therapeutics AGNCT03120000Written as PQR309
- Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma PatientsTerminatedPhase 2PIQUR Therapeutics AGNCT02850744Written as PQR309
- A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309CompletedPhase 1PIQUR Therapeutics AGNCT01940133Written as PQR309
Codes
What other systems call bimiralisib · ClinicalTrials.gg INT015348
- UNII (FDA) 6Z3QHB00LBBIMIRALISIBOne source FDA
- NCI Thesaurus C111898BimiralisibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6Z3QHB00LB | BIMIRALISIB | One source FDA |
| NCI Thesaurus | C111898 | Bimiralisib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.